Could a drug for schizophrenia work differently in men and women?

NCT ID NCT07122895

Recruiting now Symptom relief Sponsor: China Medical University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether an NMDA-enhancing drug can improve negative symptoms of schizophrenia (like lack of motivation or social withdrawal) and if it works better in men or women. 90 people with stable schizophrenia will receive either the drug or a placebo for several weeks. Researchers will measure changes in symptom scales to see if sex influences the treatment's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NMDA enhancer (NMDAE)
What this could lead to: If successful, this could point toward a more personalized treatment for negative symptoms of schizophrenia, tailored by sex.
What could go wrong: This is an early phase 2 trial with only 90 participants, so results may not apply broadly. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Department of Psychiatry, China Medical University Hospital
RECRUITING

Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.